Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice
Metrics: PDF 1414 views | HTML 1845 views | ?
Li Hua1, Mingli Fang2, Boqi Dong1, Sheng Guo2, Cuiyun Cui1, Jiwei Liu2, Yun Yao2, Yue Xiao2, Xin Li2, Yunjia Ren2, Xiuping Meng1, Xu Hao1, Peiyan Zhao2, Yilan Song1, Liying Wang2, Yongli Yu1
1Department of Immunology, College of Basic Medical Sciences, Norman Bethune Health Science Center, Jilin University, Changchun, Jilin 130021, China
2Department of Molecular Biology, College of Basic Medical Sciences, Norman Bethune Health Science Center, Jilin University, Changchun, Jilin 130021, China
Liying Wang, email: [email protected]
Yongli Yu, email: [email protected]
Keywords: NKG2DL, allogeneic tumors, early stage, NK cells, NKG2D+ cells
Received: October 12, 2015 Accepted: June 09, 2016 Published: July 19, 2016
Allogeneic tumors are eventually rejected by adaptive immune responses, however, little is known about how allogeneic tumors are eradicated at the early stage of tumor development. In present study, we found that NKG2DL low expressing cancer cells were developed into palpable allogeneic tumors in mice within a week after the inoculation, while NKG2DL high expressing cancer cells failed to. The NKG2DL high expressing cancer cells could increase NKG2D+ NK cells in the allogeneic mice after being inoculated for 3 days. Artificially up-regulating NKG2DL on cancer cells with low level expressed NKG2DL by a CpG ODN resulted in the retardation and rejection of the allogeneic tumors at the early stage. The contribution of up-regulated NKG2DL to the early rejection was further confirmed by the results that the development of allogeneic tumors from cancer cells transfected with NKG2DL genes was significantly inhibited in mice at the early stage. Overall, hopefully, the data may provide insights for combining the allogeneic NK cell adoptive transfer with the approaches of up-regulating NKG2DL to treat cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.